ADHD Clinical Trial - Benefits of ADHD Treatment in Detained People

Status Recruiting

Clinical Trial Summary

Attention deficit hyperactivity disorder (ADHD) is characterized by difficulties paying attention, poor impulse control, and hyperactive behaviors. It is associated with several health and social detrimental outcomes and leads to increased risks of criminality and recidivism. However, to date, ADHD treatment has been neglected in prison. This project will test the efficacy of ADHD treatment using a randomized controlled trial.

Clinical Trial Description

This project aims to compare the efficacy of a three-month in-prison OROS-methylphenidate vs. placebo treatment on the severity of ADHD core symptoms. Secondary outcomes address additional important in-prison and post-prison aspects: 1) reduction in acute events in prison (e.g., disciplinary sanctions, violence, misuse of ADHD treatment), 2) evaluation of the risk of recidivism upon release, 3) three-month side effects of treatment, 4) in- and post-prison adherence to medication, 5) in- and post-prison study retention, 6) in- and post-prison costs-benefits of treatment, and 8) one-year recidivism. The post-prison part of the project will highlight long-lasting benefits of a treatment provided while people are detained. These research questions will be answered using a randomized controlled trial. After randomization, the participants will undertake three months of treatment with OROS-MPH or placebo (1:1 ratio) while they are incarcerated. Upon release, all participants will be offered the possibility to have the treatment, but they will remain blinded regarding their initial study group. All of them will benefit of a cognitive-behavioral psycho-education program during detention and a cognitive-behavioral therapy after release. The RCT will provide empirical-based evidence of the benefits of in-prison ADHD treatment using different perspectives: Clinical, behavioral, recidivism-related, and economical. The investigators expect that early detection and treatment of ADHD in prison will be an important public health opportunity and a cost-effective approach, likely to decrease the vulnerability of people living in detention and to promote pathways out criminal involvement. ;

Study Design

Related Conditions & MeSH terms

ADHD

Clinical Trial Details

NCT number	NCT05842330
Study type	Interventional
Source	University Hospital, Geneva
Contact
Status	Recruiting
Phase	Phase 3
Start date	March 1, 2024
Completion date	October 30, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03148782` - Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase	N/A
Recruiting	`NCT06038942` - Formal Versus Informal Mindfulness Among University Students With Self-reported ADHD, Nonsuicidal Self-injury, or Stress	N/A
Not yet recruiting	`NCT06456372` - Digital Health Intervention for Children With ADHD	N/A
Completed	`NCT05518435` - Managing Young People With ADHD in Primary Care Study
Active, not recruiting	`NCT04978792` - Does Cultivating Self-compassion Improve Resilience to Criticism and Improve Mental Health in Adults With ADHD?	N/A
Completed	`NCT03216512` - Effects of Noise Cancelling Headphones on Neurocognitive and Academic Outcomes in ADHD	N/A
Completed	`NCT02829528` - Little Flower Yoga for Kids: Evaluation of a Yoga and Mindfulness Program for Children With Increased Levels of Emotion Dysregulation and Inattention	N/A
Completed	`NCT02900144` - Modified Comprehensive Behavioral Intervention for Tics (M_CBIT)	N/A
Not yet recruiting	`NCT02906501` - Effect of Risperidone on Cognitive Functions in Adolescents With ADHD and Behavioral Disturbances	N/A
Terminated	`NCT02271880` - Improving Medication Adherence in ADHD Adolescents	N/A
Completed	`NCT02562469` - ACTIVATE: A Computerized Training Program for Children With ADHD	N/A
Recruiting	`NCT02255565` - Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study	Phase 4
Completed	`NCT02463396` - Mindfulness Training in Adults With ADHD	N/A
Completed	`NCT01673594` - Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist	Phase 4
Terminated	`NCT01733680` - Amiloride Hydrochloride as an Effective Treatment for ADHD	Early Phase 1
Completed	`NCT02300597` - Internet-based Support for Young People With ADHD and Autism - a Controlled Study	N/A
Active, not recruiting	`NCT01137318` - Combined Cognitive Remediation and Behavioral Intervention for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)	Phase 2
Completed	`NCT01404273` - Functional MRI of Relaxation Response Training in Adults With Attention-Deficit/Hyperactivity Disorder	N/A
Completed	`NCT00586157` - Study of Medication Patch to Treat Children Ages 6-12 With ADHD	Phase 4
Completed	`NCT00573859` - The Reinforcing Mechanisms of Smoking in Adult ADHD	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.